Updated on 2023/03/10

写真a

 
SUNAGAWA Masaki
 
Organization
Graduate School of Medicine Department of Surgery, Division of Perioperative Medicine Endowed Chair Designated assistant professor
Title
Designated assistant professor
Contact information
メールアドレス

Degree 2

  1. 博士(医学) ( 2017.3   名古屋大学 ) 

  2. 学士(医学) ( 2005.3   島根大学 ) 

Research Interests 8

  1. Sarcoma

  2. Pancreatic cancer

  3. Translational research

  4. Surgical Oncology

  5. Metabolomics

  6. Gene mutation

  7. Cholangiocarcinoma/ Bile duct cancer

  8. Metabolomics

Research Areas 5

  1. Life Science / Digestive surgery

  2. Life Science / Tumor diagnostics and therapeutics

  3. Life Science / Laboratory animal science

  4. Life Science / Biomaterials

  5. Life Science / General surgery and pediatric surgery

Current Research Project and SDGs 2

  1. 希少癌早期発見パネルの開発

  2. アシドーシス環境下における癌悪性化機構の解明と新規治療方針の開発

Research History 2

  1. Nagoya University Graduate School of Medicine   Division of preoperative surgery, division of surgery   Designated assistant professor

    2021.4

      More details

    Country:Japan

  2. Columbia University Irving cancer research center   Division of digestive disease

    2017.5 - 2020.3

      More details

    Country:United States

Education 2

  1. Nagoya University   School of Medicine

    2013.4 - 2017.3

      More details

    Country: Japan

  2. Shimane University

    1999.4 - 2005.3

Professional Memberships 15

  1. 日本臨床外科学会

  2. 日本外科学会

  3. 日本消化器外科学会

  4. 日本癌学会

  5. 日本人類遺伝学会

    2021.7

  6. 日本消化器外科学会   専門医・指導医

    2012.4

  7. 日本外科学会   専門医

    2005.4

  8. American Pancreatic Association

  9. 日本サルコーマ治療研究学会

  10. 日本内視鏡外科学会

  11. 日本癌治療学会

  12. 日本肝胆膵外科学会

  13. 日本胆道学会

  14. 日本膵臓学会

  15. 日本臨床腫瘍学会

▼display all

Awards 1

  1. 47th Young Investigator awards

    2016.10   47th American Pancreatic Association   TFF1 might inhibit invasion but accelerate lymph node metastasis of pancreatic ductal adenocarcinoma

 

Papers 26

  1. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer.

    Kano MT, Kokuryo T, Baba T, Yamazaki K, Yamaguchi J, Sunagawa M, Ogura A, Watanabe N, Onoe S, Miyata K, Mizuno T, Uehara K, Igami T, Yokoyama Y, Ebata T, Nagino M

    Anticancer research   Vol. 43 ( 3 ) page: 1009 - 1016   2023.3

     More details

    Language:English  

    DOI: 10.21873/anticanres.16245

    PubMed

  2. Antitumor Effects of Deep Ultraviolet Irradiation for Pancreatic Cancer

    Yamazaki K., Kokuryo T., Yamaguchi J., Sunagawa M., Ogura A., Watanabe N., Onoe S., Miyata K., Mizuno T., Uehara K., Igami T., Yokoyama Y., Ebata T., Nagino M.

    Anticancer Research   Vol. 43 ( 2 ) page: 621 - 630   2023.2

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: Deep ultraviolet (DUV) light spans within the 250 nm to 350 nm invisible wavelength range. Although it strongly damages various cells, the efficacy of DUV irradiation on pancreatic cancer cells has never been clarified. The purpose of this study was to reveal the antitumor effects of DUV irradiation on pancreatic cancer cells. Materials and Methods: Human pancreatic cancer cell lines were eradicated with DUV or ultraviolet A (UVA) for 5 s. Several angiogenesis-related proteins were studied in cancer cells after DUV irradiation using a protein antibody array. A subcutaneous xenograft model was established by inoculation of pancreatic cancer cells into mice. Tumors in this model were irradiated with DUV or UVA once or twice for two weeks. Tumor volumes in these groups (DUV×1: one irradiation, DUV×2: two irradiations, and untreated) were analyzed one week after the second irradiation. Results: DUV irradiation significantly changed the cytomorphology of pancreatic cancer cells. In addition, DUV irradiation induced apoptosis on pancreatic cancer cells more strongly than UVA irradiation and no irradiation. Interestingly, lower expression of thrombospondin 1 (TSP1) and tissue inhibitor of metalloproteinase 1 (TIMP1) was identified after DUV treatment. The tumor volume in the DUV-treated groups (DUV×1 and DUV×2) was smaller than that in the untreated group. Conclusion: Further investigations are required to reveal the precise mechanisms of the antitumor effects of DUV irradiation and to facilitate its clinical application as a new therapy for pancreatic cancer. Overall, DUV irradiation can be potentially used as a therapeutic option of pancreatic malignancy.

    DOI: 10.21873/anticanres.16198

    Scopus

    PubMed

  3. Which modality is better to diagnose high-grade transformation in retroperitoneal liposarcoma? Comparison of computed tomography, positron emission tomography, and magnetic resonance imaging

    Nakashima Yu, Yokoyama Yukihiro, Ogawa Hiroshi, Sakakibara Ayako, Sunagawa Masaki, Nishida Yoshihiro, Mizuno Takashi, Yamaguchi Junpei, Onoe Shunsuke, Watanabe Nobuyuki, Kawakatsu Shoji, Igami Tsuyoshi, Ebata Tomoki

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY     2022.12

     More details

    Language:English   Publisher:International Journal of Clinical Oncology  

    Background: Survival in patients with retroperitoneal liposarcoma (RPLS) depends on the surgical management of the dedifferentiated foci. The present study investigated the diagnostic yield of contrast-enhanced CT, 18F-fluorodeoxyglucose positron emission tomography (PET), and diffusion-weighted MRI in terms of dedifferentiated foci within the RPLS. Methods: Patients treated with primary or recurrent RPLS who underwent the above imaging between January 2010 and December 2021 were retrospectively reviewed. The diagnostic accuracy of the three modalities for histologic subtype of dedifferentiated liposarcoma (DDLS) and French Federation of Cancer Center (FNCLCC) grade 2/3 were compared using receiver operating characteristic curves and areas under the curves (AUCs). Results: The cohort involved 32 patients with 53 tumors; 30 of which exhibited DDLS and 31 of which did FNCLCC grades 2/3. The optimal thresholds for predicting DDLS were mean CT value of 31 Hounsfield Unit (HU) (AUC = 0.880, 95% CI 0.775–0.984; p < 0.001), maximum standardized uptake value (SUVmax) of 2.9 (AUC = 0.865 95% CI 0.792–0.980; p < 0.001), while MRI failed to differentiate DDLS. The cutoff values for distinguishing FNCLCC grades 1 and 2/3 were a mean CT value of 24 HU (AUC = 0.858, 95% CI 0.731–0.985; p < 0.001) and SUVmax of 2.9 (AUC = 0.885, 95% CI 0.792–0.978; p < 0.001). MRI had no sufficient power to separate these grades. Conclusions: Contrast-enhanced CT and PET were useful for predicting DDLS and FNCLCC grade 2/3, while MRI was inferior to these two modalities.

    DOI: 10.1007/s10147-022-02287-6

    Web of Science

    Scopus

    PubMed

  4. Is a specific T classification needed for extrahepatic intraductal papillary neoplasm of the bile duct (IPNB) type 2 associated with invasive carcinoma?

    Mitake Yasuhiro, Onoe Shunsuke, Igami Tsuyoshi, Mizuno Takashi, Yamaguchi Junpei, Sunagawa Masaki, Watanabe Nobuyuki, Kawakatsu Shoji, Shimoyama Yoshie, Ebata Tomoki

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES     2022.11

     More details

    Language:English   Publisher:Journal of Hepato-Biliary-Pancreatic Sciences  

    Background: The necessity of a specific T classification for extrahepatic intraductal papillary neoplasm of the bile duct (IPNB) type 2, one of the precursors of cholangiocarcinoma (CC), remains unclear. Methods: Patients who underwent resection for extrahepatic biliary tumors were reviewed. Relapse-free survival (RFS) was compared between IPNB type 2 and CC, stratified by T classification. Results: The cohort involved 443 patients with IPNB type 2 (n = 57) and CC (n = 386). In 342 patients with perihilar tumors, 5-year RFS of IPNB type 2 and CC group was 49.8% versus 34.5% (p =.012), respectively. The RFS was 54.6% versus 47.2% (p =.110) for pT1-2 tumors and 28.6% versus 22.7% (p =.436) for pT3-4 tumors, respectively. In 92 patients with distal tumors, 5-year RFS was 47.4% versus 42.1% (p =.678). The RFS was 68.2% versus 49.6% (p =.422) for pT1 tumors and 18.8% versus 38.3% (p =.626) for pT2-3 tumors, respectively. Multivariate analysis identified that poor histologic grade (HR, 2.105; p <.001), microscopic venous invasion (HR, 1.568; p =.002), and nodal metastasis (HR, 1.547; p <.001) were independent prognostic deteriorators, while tumor type (IPNB type 2 vs. CC) was not. Conclusions: Prognostic impact of IPNB type 2 was limited, suggesting unnecessity of a specific T classification for IPNB type 2 with invasive carcinoma.

    DOI: 10.1002/jhbp.1269

    Web of Science

    Scopus

    PubMed

  5. 増刊号 術前画像の読み解きガイド-的確な術式選択と解剖把握のために Ⅶ 後腹膜 後腹膜腫瘍

    横山 幸浩, 砂川 真輝, 栗本 景介, 江畑 智希, 小寺 泰弘

    臨床外科   Vol. 77 ( 11 ) page: 325 - 329   2022.10

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1407213928

    CiNii Research

  6. METABOLOMICS OF URINARY METABOLITES IN CHILDHOOD RHABDOMYOSARCOMA TO DISCOVER NOVEL BIOMARKERS

    Nakano Satoshi, Uchida Hiroo, Amano Hizuru, Narita Atsushi, Abe Mayumi, Ishigaki Takashi, Sakairi Minoru, Shirota Chiyoe, Sumida Wataru, Makita Satoshi, Takimoto Aitaro, Okamoto Masamune, Yasui Akihiro, Takada Shunya, Nakagawa Yoichi, Terui Yasushi, Sunagawa Masaki, Takahashi Yoshiyuki, Osawa Tsuyoshi, Hinoki Akinari

    PEDIATRIC BLOOD & CANCER   Vol. 69   2022.6

     More details

    Language:Japanese  

    Web of Science

  7. Anti-Malignant Effect of Tensile Loading to Adherens Junctions in Cutaneous Squamous Cell Carcinoma Cells. International journal

    Oleg Dobrokhotov, Masaki Sunagawa, Takeru Torii, Shinji Mii, Keiko Kawauchi, Atsushi Enomoto, Masahiro Sokabe, Hiroaki Hirata

    Frontiers in cell and developmental biology   Vol. 9   page: 728383 - 728383   2021.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Actomyosin contractility regulates various cellular processes including proliferation and differentiation while dysregulation of actomyosin activity contributes to cancer development and progression. Previously, we have reported that actomyosin-generated tension at adherens junctions is required for cell density-dependent inhibition of proliferation of normal skin keratinocytes. However, it remains unclear how actomyosin contractility affects the hyperproliferation ability of cutaneous squamous cell carcinoma (cSCC) cells. In this study, we find that actomyosin activity is impaired in cSCC cells both in vitro and in vivo. External application of tensile loads to adherens junctions by sustained mechanical stretch attenuates the proliferation of cSCC cells, which depends on intact adherens junctions. Forced activation of actomyosin of cSCC cells also inhibits their proliferation in a cell-cell contact-dependent manner. Furthermore, the cell cycle arrest induced by tensile loading to adherens junctions is accompanied by epidermal differentiation in cSCC cells. Our results show that the degree of malignant properties of cSCC cells can be reduced by applying tensile loads to adherens junctions, which implies that the mechanical status of adherens junctions may serve as a novel therapeutic target for cSCC.

    DOI: 10.3389/fcell.2021.728383

    Web of Science

    Scopus

    PubMed

  8. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. International journal

    Ryota Takahashi, Marina Macchini, Masaki Sunagawa, Zhengyu Jiang, Takayuki Tanaka, Giovanni Valenti, Bernhard W Renz, Ruth A White, Yoku Hayakawa, C Benedikt Westphalen, Yagnesh Tailor, Alina C Iuga, Tamas A Gonda, Jeanine Genkinger, Kenneth P Olive, Timothy C Wang

    Gut   Vol. 70 ( 2 ) page: 330 - 341   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Long-standing chronic pancreatitis is an established risk factor for pancreatic ductal adenocarcinoma (PDAC). Interleukin-1β (IL-1β) has been associated in PDAC with shorter survival. We employed murine models to investigate the mechanisms by which IL-1β and chronic pancreatitis might contribute to PDAC progression. DESIGN: We crossed LSL-Kras +/G12D;Pdx1-Cre (KC) mice with transgenic mice overexpressing IL-1β to generate KC-IL1β mice, and followed them longitudinally. We used pancreatic 3D in vitro culture to assess acinar-to-ductal metaplasia formation. Immune cells were analysed by flow cytometry and immunohistochemical staining. B lymphocytes were adoptively transferred or depleted in Kras-mutant mice. B-cell infiltration was analysed in human PDAC samples. RESULTS: KC-IL1β mice developed PDAC with liver metastases. IL-1β treatment increased Kras+/G12D pancreatic spheroid formation. CXCL13 expression and B lymphocyte infiltration were increased in KC-IL1β pancreata. Adoptive transfer of B lymphocytes from KC-IL1β mice promoted tumour formation, while depletion of B cells prevented tumour progression in KC-IL1β mice. B cells isolated from KC-IL1β mice had much higher expression of PD-L1, more regulatory B cells, impaired CD8+ T cell activity and promoted tumorigenesis. IL-35 was increased in the KC-IL1β pancreata, and depletion of IL-35 decreased the number of PD-L1+ B cells. Finally, in human PDAC samples, patients with PDAC with higher B-cell infiltration within tumours showed significantly shorter survival. CONCLUSION: We show here that IL-1β promotes tumorigenesis in part by inducing an expansion of immune-suppressive B cells. These findings point to the growing significance of B suppressor cells in pancreatic tumorigenesis.

    DOI: 10.1136/gutjnl-2019-319912

    PubMed

  9. Is constant negative pressure for external drainage of the main pancreatic duct useful in preventing pancreatic fistula following pancreatoduodenectomy? International journal

    Masaki Sunagawa, Yukihiro Yokoyama, Junpei Yamaguchi, Tomoki Ebata, Gen Sugawara, Tsuyoshi Igami, Takashi Mizuno, Masato Nagino

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   Vol. 19 ( 4 ) page: 602 - 607   2019.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    BACKGROUND: This study sought to investigate the utility of constant negative pressure for external drainage of the main pancreatic duct in preventing postoperative pancreatic fistula (POPF) after pancreatoduodenectomy. METHODS: Only patients with soft pancreas were included. In the former period (July 2013 to May 2015), gravity dependent drainage was applied (gravity dependent drainage group), and in the latter period (June 2015 to November 2016), constant negative pressure drainage (negative pressure drainage group) was applied to the main pancreatic duct stent. RESULTS: There were 37 patients in the gravity dependent drainage group and 39 patients in the negative pressure drainage group. Clinically relevant POPF occurred in 21 patients (56.8%) in the gravity dependent drainage group and 13 patients (33.3%) in the negative pressure drainage group (p = 0.040). The incidence rate of major complications (Clavien-Dindo grade > III) was significantly lower in the negative pressure drainage group (13.2%) compared to the gravity dependent drainage group (48.7%) (p = 0.001). In-hospital stay was also significantly shorter in the negative pressure drainage group compared to the gravity dependent drainage group (median 25 vs. 33 days, p = 0.024). Multivariate analysis demonstrated that the gravity dependent drainage was one of the independent risk factors for the incidence of POPF (odds ratio, 3.33; p = 0.032). CONCLUSIONS: In patients with soft pancreas, the incidence rate of clinically relevant POPF may be reduced by applying constant negative pressure to the pancreatic duct stent. It also has a potential to reduce overall incidence of major complications and shorten in-hospital stay after pancreatoduodenectomy.

    DOI: 10.1016/j.pan.2019.04.002

    Web of Science

    Scopus

    PubMed

  10. Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. International journal

    Bernhard W Renz, Takayuki Tanaka, Masaki Sunagawa, Ryota Takahashi, Zhengyu Jiang, Marina Macchini, Zahra Dantes, Giovanni Valenti, Ruth A White, Moritz A Middelhoff, Matthias Ilmer, Paul E Oberstein, Martin K Angele, Huan Deng, Yoku Hayakawa, C Benedikt Westphalen, Jens Werner, Helen Remotti, Maximilian Reichert, Yagnesh H Tailor, Karan Nagar, Richard A Friedman, Alina C Iuga, Kenneth P Olive, Timothy C Wang

    Cancer discovery   Vol. 8 ( 11 ) page: 1458 - 1473   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    In many solid tumors, parasympathetic input is provided by the vagus nerve, which has been shown to modulate tumor growth. However, whether cholinergic signaling directly regulates progression of pancreatic ductal adenocarcinoma (PDAC) has not been defined. Here, we found that subdiaphragmatic vagotomy in LSL-Kras +/G12D;Pdx1-Cre (KC) mice accelerated PDAC development, whereas treatment with the systemic muscarinic agonist bethanechol restored the normal KC phenotype, thereby suppressing the accelerated tumorigenesis caused by vagotomy. In LSL-Kras +/G12D;LSL-Trp53 +/R172H;Pdx1-Cre mice with established PDAC, bethanechol significantly extended survival. These effects were mediated in part through CHRM1, which inhibited downstream MAPK/EGFR and PI3K/AKT pathways in PDAC cells. Enhanced cholinergic signaling led to a suppression of the cancer stem cell (CSC) compartment, CD11b+ myeloid cells, TNFα levels, and metastatic growth in the liver. Therefore, these data suggest that cholinergic signaling directly and indirectly suppresses growth of PDAC cells, and therapies that stimulate muscarinic receptors may be useful in the treatment of PDAC.Significance: Subdiaphragmatic vagotomy or Chrm1 knockout accelerates pancreatic tumorigenesis, in part via expansion of the CSC compartment. Systemic administration of a muscarinic agonist suppresses tumorigenesis through MAPK and PI3K/AKT signaling, in early stages of tumor growth and in more advanced, metastatic disease. Therefore, CHRM1 may represent a potentially attractive therapeutic target. Cancer Discov; 8(11); 1458-73. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333.

    DOI: 10.1158/2159-8290.CD-18-0046

    PubMed

  11. Suppression of skin tumorigenesis in CD109-deficient mice. International journal

    Masaki Sunagawa, Shinji Mii, Atsushi Enomoto, Takuya Kato, Yoshiki Murakumo, Yukihiro Shiraki, Naoya Asai, Masato Asai, Masato Nagino, Masahide Takahashi

    Oncotarget   Vol. 7 ( 50 ) page: 82836 - 82850   2016.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    CD109 is a glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed in several types of human cancers, particularly squamous cell carcinomas. We previously reported that CD109-deficient mice exhibit epidermal hyperplasia and chronic skin inflammation. Although we found that CD109 regulates differentiation of keratinocytes in vivo, the function of CD109 in tumorigenesis remains unknown. In this study, we investigated the role of CD109 in skin tumorigenesis using a two-stage carcinogenesis model in CD109-deficient mice with chronic skin inflammation. Immunohistochemical analysis revealed a higher level of TGF-β protein expression in the dermis of CD109-deficient mice than in that of wild-type mice. Additionally, immunofluorescence analysis showed that Smad2 phosphorylation and Nrf2 expression were enhanced in primary keratinocytes from CD109-deficient mice compared with in those from wild-type mice. Although no significant difference was found in conversion rates from papilloma to carcinoma between wild-type and CD109-deficient mice in the carcinogenesis model, we observed fewer and smaller papillomas in CD109-deficient mice than in wild-type mice. Apoptosis and DNA damage marker levels were significantly reduced in CD109-deficient skin compared with in wild-type skin at 24 h after 7, 12-dimethylbenz (α) anthracene treatment. Furthermore, mutation-specific PCR revealed that the mutation frequency of the H-ras gene was less in CD109-deficient skin than in wild-type skin in this model. These results suggest that CD109 deficiency suppresses skin tumorigenesis by enhancing TGF-β/Smad/Nrf2 pathway activity and decreasing the mutation frequency of the H-ras gene.

    DOI: 10.18632/oncotarget.12653

    Web of Science

    Scopus

    PubMed

  12. A proposal of drain removal criteria in hepatobiliary resection.

    Nobuyuki Watanabe, Takashi Mizuno, Junpei Yamaguchi, Yukihiro Yokoyama, Tsuyoshi Igami, Shunsuke Onoe, Kay Uehara, Masaki Sunagawa, Tomoki Ebata

    Journal of hepato-biliary-pancreatic sciences   Vol. 29 ( 9 ) page: 974 - 982   2022.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Standardized criteria for drain removal in hepatobiliary resection are lacking. Here, we evaluated the outcomes of delayed removal policy in this extended surgery. METHODS: Patients undergoing hepatectomy with biliary reconstruction between 2012 and 2018 were retrospectively reviewed. The drains were removed on postoperative day (POD) 7 when the drainage fluid was grossly serous, biochemically normal, and negative for bacterial contamination as assessed by Gram staining; additionally, no abnormal fluid collection was confirmed by computed tomography. Clinically relevant abdominal complications (CRACs), including biliary leakage, pancreatic fistula or intra-abdominal abscess, served as the primary outcome measure. RESULTS: Among 374 study patients, surgical drains were removed in 166 (44.3%) patients who met the criteria. Of these patients, 16 (9.6%) patients subsequently required additional drainage due to CRAC. Drains were retained and exchanged in 208 (55.6%) patients who did not meet the criteria. Of these, exchanged drains were soon removed in 34 patients due to no signs of CRAC. The diagnostic ability of the criteria revealed 0.916 sensitivity, 0.815 specificity, and 0.866 accuracy. CONCLUSION: The four findings on POD 7 worked well as criteria for drain removal, and these criteria may be helpful in drain management after hepatobiliary resection.

    DOI: 10.1002/jhbp.1194

    Web of Science

    Scopus

    PubMed

  13. 【肝胆膵癌におけるconversion therapy】胆道癌におけるconversion therapy 胆道癌conversion慎重な立場から 胆道癌におけるconversion therapyの現状と問題点

    高橋 大五郎, 水野 隆史, 尾上 俊介, 渡辺 伸元, 山口 淳平, 砂川 真輝, 上原 圭, 横山 幸浩, 江畑 智希

    肝胆膵   Vol. 84 ( 5 ) page: 669 - 677   2022.5

     More details

    Language:Japanese   Publisher:(株)アークメディア  

  14. 悪性転化した仙尾部奇形腫の2例

    西村 元伸, 上原 圭, 小倉 淳司, 村田 悠記, 三品 拓也, 小池 佳勇, 神原 祐一, 小林 龍太朗, 神野 孝徳, 國料 俊男, 伊神 剛, 水野 隆史, 山口 淳平, 宮田 一志, 尾上 俊介, 砂川 真輝, 渡辺 伸元, 杉田 静紀, 横山 幸浩, 江畑 智希

    日本外科学会定期学術集会抄録集   Vol. 122回   page: DP - 8   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  15. C.difficile関連感染症に対する酪酸菌製剤の予防効果について

    渡辺 伸元, 水野 隆史, 尾上 俊介, 横山 幸浩, 伊神 剛, 山口 淳平, 砂川 真輝, 江畑 智希

    日本外科学会定期学術集会抄録集   Vol. 122回   page: DP - 8   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  16. 切除可能同時性肝転移症例の治療戦略 肝実質温存術式の有用性

    三品 拓也, 水野 隆史, 上原 圭, 小倉 淳司, 村田 悠記, 小池 佳勇, 神原 祐一, 西村 元伸, 小林 龍太朗, 服部 憲史, 中山 吾郎, 國料 俊男, 伊神 剛, 山口 淳平, 宮田 一志, 尾上 俊介, 砂川 真輝, 渡辺 伸元, 横山 幸浩, 江畑 智希

    日本外科学会定期学術集会抄録集   Vol. 122回   page: SF - 7   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  17. 【ガイドラインには書いていない 大腸癌外科治療のCQ-妥当な治療と適応を見直そう】高度進行大腸癌への術前治療を分子標的薬別に考える Total neoadjuvant therapy・triplet時代における術前治療の最新エビデンス

    小倉 淳司, 上原 圭, 村田 悠記, 水野 隆史, 國料 俊男, 伊神 剛, 山口 淳平, 宮田 一志, 尾上 俊介, 砂川 真輝, 渡辺 伸元, 杉田 静紀, 横山 幸浩, 江畑 智希

    臨床外科   Vol. 77 ( 2 ) page: 199 - 206   2022.2

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>ポイント ◆局所進行直腸癌に対し,術前CRTへの分子標的薬併用による局所制御・生存率への上乗せ効果は証明されていない.一方,NACやinduction chemotherapyへの分子標的薬併用による局所制御への上乗せ効果の報告は散見される.◆Stage IV・再発大腸癌では,分子標的薬を併用することで奏効率・腫瘍縮小率が上昇し,原発巣・遠隔転移巣ともR0切除やconversion手術のチャンスが増加する.◆"Cure"をめざした術前治療との併用こそが,分子標的薬の真の使いどころかもしれない.

  18. 【胆道癌治療の最前線】肝外胆管癌に対する手術術式と適応

    尾上 俊介, 水野 隆史, 渡辺 伸元, 横山 幸浩, 國料 俊男, 伊神 剛, 上原 圭, 山口 淳平, 宮田 一志, 砂川 真輝, 小倉 淳司, 江畑 智希

    外科   Vol. 84 ( 2 ) page: 136 - 141   2022.2

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>肝外胆管癌は,非治癒因子が存在しない限り根治切除をめざす.肝外胆管癌は肝門部領域胆管癌と遠位胆管癌に分類され,それぞれ尾状葉を伴う肝葉切除・肝外胆管切除術,膵頭十二指腸切除術(pancreaticoduodenectomy:PD)が標準術式となる.肝門部領域胆管癌に対する肝切除術式を決定する際はBismuth分類が有用である.遠位胆管癌のPDの術式は,胃切除範囲や再建法にバリエーションがあり,上腸間膜動脈周囲リンパ節郭清はリンパ節の適正評価に有用である.これら肝外胆管癌の手術適応は癌遺残度の可能性,血管浸潤,リンパ節転移などの腫瘍因子を考慮したうえで決定する.

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2022&ichushi_jid=J00393&link_issn=&doc_id=20220128060007&doc_link_id=10.15106%2Fj_geka84_136&url=https%3A%2F%2Fdoi.org%2F10.15106%2Fj_geka84_136&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  19. 切除不能同時性肝肺転移を有する直腸癌に対してFOLFOXIRI+bevacizumab療法で奏功が得られ二期的にR0切除し得た1例

    村田 悠記, 水野 隆史, 上原 圭, 小倉 淳司, 三品 拓也, 小池 佳勇, 神原 祐一, 西村 元伸, 小林 龍太郎, 神野 孝徳, 國料 俊男, 伊神 剛, 山口 淳平, 宮田 一志, 尾上 俊介, 砂川 真輝, 渡辺 伸元, 杉田 静紀, 横山 幸浩, 江畑 智希

    日本消化器病学会東海支部例会プログラム抄録集   Vol. 135回   page: 81 - 81   2021.12

     More details

    Language:Japanese   Publisher:日本消化器病学会-東海支部  

  20. 【胆道狭窄の診断と治療】各論(治療) 肝門部領域胆管癌に対する手術適応と術式選択

    尾上 俊介, 水野 隆史, 渡辺 伸元, 横山 幸浩, 伊神 剛, 上原 圭, 山口 淳平, 砂川 真輝, 江畑 智希

    肝胆膵   Vol. 83 ( 5 ) page: 819 - 823   2021.11

     More details

    Language:Japanese   Publisher:(株)アークメディア  

  21. 後腹膜肉腫に対する集学的治療 原発および再発後腹膜脂肪肉腫の外科治療 単施設における積極的手術療法の術後成績

    横山 幸浩, 石井 健太, 砂川 真輝, 西田 佳弘, 栗本 景介, 小寺 泰弘, 江畑 智希

    日本癌治療学会学術集会抄録集   Vol. 59回   page: SY16 - 2   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

  22. 後腹膜肉腫初回手術後再発症例の治療戦略

    砂川 真輝, 横山 幸浩, 伊神 剛, 水野 隆史, 山口 淳平, 尾上 俊介, 渡辺 伸元, 江畑 智希

    日本癌治療学会学術集会抄録集   Vol. 59回   page: P43 - 1   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

  23. 【知っておくべき!最新の大腸外科局所解剖】結腸脾彎曲の外科解剖

    相場 利貞, 上原 圭, 小倉 淳司, 村田 悠記, 砂川 真輝, 渡辺 伸元, 尾上 俊介, 宮田 一志, 山口 淳平, 水野 隆史, 伊神 剛, 國料 俊男, 横山 幸浩, 江畑 智希

    消化器外科   Vol. 44 ( 9 ) page: 1409 - 1415   2021.8

     More details

    Language:Japanese   Publisher:(株)へるす出版  

  24. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer

    Sunagawa Masaki, Yamaguchi Junpei, Kokuryo Toshio, Ebata Tomoki, Yokoyama Yukihiro, Sugawara Gen, Nagino Masato

    PANCREATOLOGY   Vol. 17 ( 5 ) page: 782 - 787   2017

     More details

    Language:Japanese   Publisher:Pancreatology  

    Objectives Trefoil Factor Family protein 1 (TFF1) is secreted from mucus-producing cells. The relationship between TFF1 expression and clinical outcome in pancreatic ductal adenocarcinoma (PDAC) remains unknown. We aimed to evaluate the prognostic significance of TFF1 expression in PDAC. Methods TFF1 expression was examined on paraffin-embedded sections from 91 patients with resected PDAC using immunohistochemistry. The relationships between TFF1 expression and clinicopathological features were analyzed. Results Among 91 PDAC patients, 71 patients (79.7%) showed TFF1 expression in cancer cells. In a subgroup of 71 patients, TFF1 expression was predominantly observed in the central part of the tumor, whereas TFF1 expression in the invasion front was reduced in 33 patients (46.4%). A significant correlation between preserved TFF1 expression in the invasion front and lymph node metastasis was observed. Univariate survival analysis revealed that preserved TFF1 expression in the invasion front, positive lymphatic invasion, lymph node metastasis and R1 resection was a significant poor prognostic factor in TFF1-positive PDAC patients. Conclusions TFF1 expression is frequently lost or decreased in the invasion front of human PDAC, and preserved TFF1 expression in the invasion front might predict poor survival in patients with PDAC.

    DOI: 10.1016/j.pan.2017.07.188

    Web of Science

    Scopus

    PubMed

  25. TFF1 Might Inhibit Invasion but Accelerate Lymph Node Metastasis of Pancreatic Ductal Adenocarcinoma

    Sunagawa M., Yamaguchi J., Yokoyama Y., Kokuryo T., Nagino M.

    PANCREAS   Vol. 45 ( 10 ) page: 1540 - 1540   2016.11

     More details

    Language:Japanese  

    Web of Science

  26. Lower grade gliomaにおける免疫組織化学染色でのCD109の発現は、予後と相関する

    白木 之浩, 砂川 真輝, 三井 伸二, 浅井 直也, 榎本 篤, 百田 洋之, 夏目 敦至, 若林 俊彦, 高橋 雅英

    日本癌学会総会記事   Vol. 75回   page: P - 2260   2016.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

▼display all

MISC 3

  1. FOCUS 後腹膜肉腫診療ガイドラインの要点と今後の展望

    横山 幸浩, 砂川 真輝, 栗本 景介, 江畑 智希, 小寺 泰弘

    臨床外科   Vol. 77 ( 9 ) page: 1108 - 1112   2022.9

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1407213835

    CiNii Research

  2. 特集 直腸癌局所再発に挑む-最新の治療戦略と手術手技 総論 局所再発直腸癌の治療方針-臓器温存手術や遠隔転移併存症例の手術適応も含めて

    村田 悠記, 上原 圭, 小倉 淳司, 杉田 静紀, 渡辺 伸元, 砂川 真輝, 尾上 俊介, 宮田 一志, 山口 淳平, 水野 隆史, 伊神 剛, 國料 俊男, 横山 幸浩, 江畑 智希

    臨床外科   Vol. 77 ( 5 ) page: 514 - 519   2022.5

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1407213704

    CiNii Research

  3. 特集 胆道癌治療の最前線 II. 各論 4.肝外胆管癌に対する手術術式と適応

    尾上 俊介, 水野 隆史, 渡辺 伸元, 横山 幸浩, 國料 俊男, 伊神 剛, 上原 圭, 山口 淳平, 宮田 一志, 砂川 真輝, 小倉 淳司, 江畑 智希

    外科   Vol. 84 ( 2 ) page: 136 - 141   2022.2

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka84_136

    CiNii Research

Presentations 5

  1. pH regulation might increase drug sensitiveity      in pancreatic ductal adenocarinoma

    Maski Sunagawa

    2022.10.1 

     More details

    Event date: 2022.9 - 2022.10

    Presentation type:Poster presentation  

  2. Sarcopenia predicts poor therapeutic response and prognosis in patients with pancreatic cancer after neoadjuvant chemotherapy

    2022.6.10 

     More details

    Event date: 2022.6

    Language:English   Presentation type:Symposium, workshop panel (public)  

  3. Resection of retroperitoneal soft tissue sarcoma that required combined vascular resection

    2022.7.21 

     More details

    Event date: 2022.7

    Presentation type:Symposium, workshop panel (public)  

  4. 血管合併切除再検を要した後腹膜悪性軟部腫瘍の手術経験

    砂川 真輝

    日本サルコーマ治療研究学会学術集会  2022.2.5  日本サルコーマ治療研究学会学術集会

     More details

    Event date: 2022.2

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:京都  

  5. 後腹膜肉腫初回手術後再発症例の治療選択

    砂川真輝, 横山幸浩, 伊神剛, 水野隆史, 山口淳平, 尾上俊介, 渡辺伸元, 江畑智希

    第59回日本がん治療学会学術集会  2021.10.23 

     More details

    Event date: 2021.10

    Language:Japanese   Presentation type:Poster presentation  

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. 胆道癌における融合型ノンコーディングRNAの機能解明と臨床応用

    Grant number:22K08820  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    國料 俊男, 江畑 智希, 横山 幸浩, 山口 淳平, 砂川 真輝

      More details

    Authorship:Coinvestigator(s) 

    融合型ノンコーディングRNA(融合型ncRNA)はタンパク合成をしないにもかかわらず、多くの遺伝子制御に関与し、生体内で重要な役割を果たしている。また融合遺伝子が癌の機能や制御に関与していることも報告されている。われわれは胆管癌での全ゲノム解析により、異なる2つのノンコーディングRNAからなる融合型ncRNAを十数種類同定した。融合型ncRNAの存在は未知のメカニズムの存在を示唆しており、融合遺伝子同様にノンコーディングRNAの機能不全や異常シグナルの活性化など癌化への関与が考えられる。融合型ncRNAの機能解析により関連遺伝子など未知の癌化メカニズムを解明し新規癌治療戦略を構築する。

  2. 弱酸性腫瘍間質液のpH制御による抗癌剤治療効果の検討

    Grant number:21K20800  2021.8 - 2023.3

    日本学術振興会  科学研究費助成事業 研究活動スタート支援  研究活動スタート支援

    砂川 真輝

      More details

    Authorship:Principal investigator 

    Grant amount:\3120000 ( Direct Cost: \2400000 、 Indirect Cost:\720000 )

    膵臓癌は豊富な癌微小環境を伴う難治癌の1つである。癌微小環境中の腫瘍間質液(Tumor Interstitial Fluid; TIF)は癌の生育に関して重要とされている。腫瘍微小環境中の豊富な乳酸が間質液により溶解することで弱酸性となったTIFは腫瘍の悪性化を進行させることは知られているが、抗癌剤耐性獲得能については検討されていない。本研究の目的は(1)弱酸性細胞外環境が誘導する抗癌剤耐性関連遺伝子の解析およびシグナルの検索および(2)弱酸性TIFのpH制御による抗癌剤の抗腫瘍効果をマウスモデルで検証する。

 

Teaching Experience (On-campus) 5

  1. 外科総論 膵臓がんの

    2022

     詳細を見る

    膵臓がんの臨床・基礎研究
    Clinical questionの立案方法

  2. 外科基本手技の継承

    2022

  3. 臨床実習指導

    2022

     詳細を見る

    Bedside learning

  4. 問題解決型学習

    2022

     詳細を見る

    心疾患症例の検討をグループディスカッションで行った。

  5. 客観的臨床能力試験

    2022

     詳細を見る

    客観的臨床能力試験